First-line chemotherapy with liposomal doxorubicin plus cyclofosfamide in metastatic breast cancer: A case report of early and prolonged response

Ferdinando Riccardi, C. Mocerino, C. Barbato, F. Ambrosio, L. Festino, M. G. Vitale, G. Carrillo, M. Trunfio, S. Minelli, G. Cartenì

Research output: Contribution to journalArticle

Abstract

The treatment choice for metastatic breast cancer should consider the appropriate balance between efficacy and toxicity of the therapy. We discuss a clinical case with an early response and prolonged to liposomal anthracyclines-based chemotherapy, without cardiotoxicity, enhancing the evidence of safety of liposomal formulation to prevent heart damage. Moreover, the case seems to be of interest for the role of 18F-FDG-PET in clinical response assessment: an early decrease of the standardized uptake value value, even before conventional imaging evaluation, is highly predictive for prolonged clinical response.

Original languageEnglish
Pages (from-to)773-778
Number of pages6
JournalInternational Journal of Immunopathology and Pharmacology
Volume26
Issue number3
Publication statusPublished - Jul 2013

Fingerprint

Breast Neoplasms
Drug Therapy
Anthracyclines
Fluorodeoxyglucose F18
Safety
Therapeutics
liposomal doxorubicin
Cardiotoxicity

Keywords

  • First-line chemotherapy
  • Metastatic breast cancer
  • Non-pegylated liposomal doxorubicin
  • Positron emission tomography

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Cite this

First-line chemotherapy with liposomal doxorubicin plus cyclofosfamide in metastatic breast cancer : A case report of early and prolonged response. / Riccardi, Ferdinando; Mocerino, C.; Barbato, C.; Ambrosio, F.; Festino, L.; Vitale, M. G.; Carrillo, G.; Trunfio, M.; Minelli, S.; Cartenì, G.

In: International Journal of Immunopathology and Pharmacology, Vol. 26, No. 3, 07.2013, p. 773-778.

Research output: Contribution to journalArticle

Riccardi, F, Mocerino, C, Barbato, C, Ambrosio, F, Festino, L, Vitale, MG, Carrillo, G, Trunfio, M, Minelli, S & Cartenì, G 2013, 'First-line chemotherapy with liposomal doxorubicin plus cyclofosfamide in metastatic breast cancer: A case report of early and prolonged response', International Journal of Immunopathology and Pharmacology, vol. 26, no. 3, pp. 773-778.
Riccardi, Ferdinando ; Mocerino, C. ; Barbato, C. ; Ambrosio, F. ; Festino, L. ; Vitale, M. G. ; Carrillo, G. ; Trunfio, M. ; Minelli, S. ; Cartenì, G. / First-line chemotherapy with liposomal doxorubicin plus cyclofosfamide in metastatic breast cancer : A case report of early and prolonged response. In: International Journal of Immunopathology and Pharmacology. 2013 ; Vol. 26, No. 3. pp. 773-778.
@article{f5940a34817b43adaf9c9578ea4816ad,
title = "First-line chemotherapy with liposomal doxorubicin plus cyclofosfamide in metastatic breast cancer: A case report of early and prolonged response",
abstract = "The treatment choice for metastatic breast cancer should consider the appropriate balance between efficacy and toxicity of the therapy. We discuss a clinical case with an early response and prolonged to liposomal anthracyclines-based chemotherapy, without cardiotoxicity, enhancing the evidence of safety of liposomal formulation to prevent heart damage. Moreover, the case seems to be of interest for the role of 18F-FDG-PET in clinical response assessment: an early decrease of the standardized uptake value value, even before conventional imaging evaluation, is highly predictive for prolonged clinical response.",
keywords = "First-line chemotherapy, Metastatic breast cancer, Non-pegylated liposomal doxorubicin, Positron emission tomography",
author = "Ferdinando Riccardi and C. Mocerino and C. Barbato and F. Ambrosio and L. Festino and Vitale, {M. G.} and G. Carrillo and M. Trunfio and S. Minelli and G. Carten{\`i}",
year = "2013",
month = "7",
language = "English",
volume = "26",
pages = "773--778",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "3",

}

TY - JOUR

T1 - First-line chemotherapy with liposomal doxorubicin plus cyclofosfamide in metastatic breast cancer

T2 - A case report of early and prolonged response

AU - Riccardi, Ferdinando

AU - Mocerino, C.

AU - Barbato, C.

AU - Ambrosio, F.

AU - Festino, L.

AU - Vitale, M. G.

AU - Carrillo, G.

AU - Trunfio, M.

AU - Minelli, S.

AU - Cartenì, G.

PY - 2013/7

Y1 - 2013/7

N2 - The treatment choice for metastatic breast cancer should consider the appropriate balance between efficacy and toxicity of the therapy. We discuss a clinical case with an early response and prolonged to liposomal anthracyclines-based chemotherapy, without cardiotoxicity, enhancing the evidence of safety of liposomal formulation to prevent heart damage. Moreover, the case seems to be of interest for the role of 18F-FDG-PET in clinical response assessment: an early decrease of the standardized uptake value value, even before conventional imaging evaluation, is highly predictive for prolonged clinical response.

AB - The treatment choice for metastatic breast cancer should consider the appropriate balance between efficacy and toxicity of the therapy. We discuss a clinical case with an early response and prolonged to liposomal anthracyclines-based chemotherapy, without cardiotoxicity, enhancing the evidence of safety of liposomal formulation to prevent heart damage. Moreover, the case seems to be of interest for the role of 18F-FDG-PET in clinical response assessment: an early decrease of the standardized uptake value value, even before conventional imaging evaluation, is highly predictive for prolonged clinical response.

KW - First-line chemotherapy

KW - Metastatic breast cancer

KW - Non-pegylated liposomal doxorubicin

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=84887465615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887465615&partnerID=8YFLogxK

M3 - Article

C2 - 24067476

AN - SCOPUS:84887465615

VL - 26

SP - 773

EP - 778

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 3

ER -